Do not treat all CLL patients with fludarabine by Bosanquet, A, Johnson, SA, Richards, S

Prognosis for fludarabine therapy of chronic lymphocytic leukaemia based on ex vivo drug response by DiSC assay. by Bosanquet, A, Johnson, SA, Richards, S

High mortality of DiSC assay-resistant CLL patients treated with fludarabine. by Bosanquet, A, Johnson, SA, Richards, S

The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry. by Matutes, E, Bosanquet, A, Wade, R, Richards, S, Else, M, Catovsky, D

The use of individualized tumor response testing in treatment selection: Second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry by Matutes, E, Bosanquet, A, Wade, R, Richards, S, Else, M, Catovsky, D

Drug sensitivity by TRAC (DISC) assay as a prognostic factor for patient response in untreated CLL: Results from the UK LRF CLL4 trial. by Bosanquet, A, Raper, S, Durant, J, Scadding, S, Oscier, D, Richards, S, Catovsky, D, Grp, N

Drug cross-resistance and therapy-induced resistance in chronic lymphocytic leukaemia by an enhanced method of individualised tumour response testing. by Bosanquet, A, Richards, S, Wade, R, Else, M, Matutes, E, Dyer, M, Rassam, S, Durant, J, Scadding, S, Raper, S, Dearden, C, Catovsky, D

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. by Catovsky, D, Richards, S, Matutes, E, Oscier, D, Dyer, M, Bezares, R, Pettitt, A, Hamblin, T, Milligan, D, Child, J, Hamilton, MS, Dearden, C, Smith, A, Bosanquet, A, Davis, Z, Brito-Babapulle, V, Else, M, Wade, R, Hillmen, P